Table 6.

Quality of life analyses from randomized controlled trials.

Reference	Trial	N patients	Main results
Bordoni et al. (75)	OAK (atezolizumab vs. docetaxel)	803	HRQoL: HR 0.94 (95% CI 0.72–1.24; p = 0.66) TTD in physical function: HR 0.75 (95% CI 0.58–0.98; p = 0.03) TTD in role function: HR 0.79 (95% CI, 0.62–1.00; p = 0.05) TTD in chest pain: HR 0.71 (95% CI 0.49–1.05; p = 0.08)
Reck et al. (76)	Checkmate 057 (nivolumab vs. docetaxel in non-squamous NSCLC)	420	LCSS ABSI: HR 0.65 (95% CI 0.49–0.85; p = 0.002) LCSS-3-IGI : HR 0.63 (95% CI 0.48–0.82; p < 0.001) EQ-5D utility index : HR 0.90 (95% CI 0.69–1.17; p = 0.42) EQ-5D VAS : HR 0.76 (95% CI 0.59–0.98; p = 0.032)
Reck et al. (77)	Checkmate 017 (nivolumab vs. docetaxel in squamous NSCLC)	181	LCSS ABSI: HR 0.67 (95% CI 0.43–1.03; p = 0.07) LCSS-3-IGI : HR 0.57 (95% CI 0.38–0.85; p = 0.005) EQ-5D utility index : HR 0.55 (95% CI 0.36–0.84; p = 0.006) EQ-5D VAS : HR 0.59 (95% CI 0.40–0.87; p = 0.008)
Brahmer et al. (78)	Keynote 024 (pembrolizumab vs. platinum-CT, PDL1>50%)	299	At week 15: improvement of QLQ C30 of 7.8 points (2.9–12.8; p = 0.002) TTD (pembrolizumab vs. CT): median not reached vs. 5.0 months (HR 0.66, 95% CI 0.44–0.97; p = 0.029)

HRQoL, health related quality of life; HR, hazard ratio; CI, confidence interval; TTD, time to deterioration; NSCLC, non-small cell lung cancer; CT, chemotherapy.